10x Genomics (TXG) Cash & Current Investments (2018 - 2026)

10x Genomics has disclosed Cash & Current Investments across 9 years of filings, most recently posting $539.8 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $539.8 million, up 26.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $539.8 million (up 26.46% YoY), and the FY2025 annual result was $523.4 million, up 33.05% from the prior year.
• Cash & Current Investments came in at $539.8 million for Q1 2026 at 10x Genomics, up from $523.4 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $539.8 million in Q1 2026 to a low of $222.4 million in Q4 2022.
• The 5-year median for Cash & Current Investments is $391.4 million (2023), against an average of $394.4 million.
• Across the five-year window, Cash & Current Investments slumped 62.21% in 2022 and soared 74.79% in 2023, its largest moves.
• 10x Genomics' Cash & Current Investments stood at $222.4 million in 2022, then jumped by 74.79% to $388.7 million in 2023, then grew by 1.21% to $393.4 million in 2024, then soared by 33.05% to $523.4 million in 2025, then increased by 3.14% to $539.8 million in 2026.
• The last three Cash & Current Investments figures came in at $539.8 million (Q1 2026), $523.4 million (Q4 2025), and $482.1 million (Q3 2025), per Business Quant data.